Resources

MORF-Bio is delighted to announce the successful closing of its pre-seed funding round to accelerate development of its microbial bioinformatics software.

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.

Executive with broad and deep experience across energy and healthcare sectors joins the life sciences leader to drive growth in resins, filtration, and cell culture media business.

In this blog, Tom Sheldon, Senior Manager at the Science Media Centre (SMC), explores how scientists and communicators are taking on misinformation head-on — and how the SMC’s work supports both researchers and journalists in helping the public make sense of complex, and sometimes controversial, scientific issues.

Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell Therapy Grade proteins, engineered to support the stringent requirements of cell therapy research, process development, and GMP manufacturing.

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Medannex's novel therapy MDX-124, for the treatment of biliary tract cancer (BTC). The FDA’s decision is based on emerging clinical data from the ongoing first-in-human Phase 1b ATTAINMENT clinical trial, which shows promising efficacy signals in patients treated with MDX-124 monotherapy. Durable disease control and tumour shrinkage have been observed in several BTC patients, with no significant side effects. 

Chemify scales up operations at Glasgow’s newest purpose-built life science facility Health Innovation Hub. Chemify joins the Digital Health Validation Lab (DHVL) who will all be welcomed as the first tenants of HiH when it opens this year.

Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, today announces the appointment of Dr. Katie Chapman as Chief Scientific Officer (CSO).

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Parkinson’s UK and is pleased to announce the placement of Dr. Lynsey Bilsland as Managing Director of Parkinson’s Virtual Biotech.

Ellie Avni, Senior Director in Employment Tax and Reward at FTI Consulting, explores how the new PISCES platform could reshape EMI and CSOP share option plans – creating fresh opportunities for flexibility and tax-efficient value realisation.

PACE (Pathways to Antimicrobial Clinical Efficacy) launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health.

VectorBuilder wins two IMAPAC awards, cementing leadership in gene therapy and CDMO innovation

The BIA moves into a new era this week, amidst news from the US on tariffs for UK pharma, UK political party conferences underway and a change in leadership at GSK. It’s full steam ahead for BIA towards a busy Autumn, ensuring that the life science sector stays at the top of the government’s priority list and that our members are represented and connected.

The Life Sciences Learner Hub – the evolution of the proven ATSTN Online Training Platform, now expanded to serve the broader life sciences community.

Darren Blamire, Autolus, and Diana Hernandez, Anthony Nolan, will steer BIA’s Cell and Gene Therapy Advisory Committee, driving UK leadership and patient access in this transformative field.

Announcement of a placement, working with an international biotech backed by UK and global VCs.

New Moderna Innovation and Technology Centre opened as government further boosts life sciences sector with £50 million fund.

This strategic hire marks a significant step in the firm’s expansion within the Swiss market and the broader DACH region.